Drugs / Temsirolimus
last change 17 days ago re-read 2 minutes ago

Temsirolimus

Small molecule targets FKBP1A, MTOR via inhibition

Developed for
renal cell carcinoma · cancer of unknown primary site · cancer · adult glioblastoma · gliosarcoma · mantle cell lymphoma · endometrial carcinoma · metastatic malignant neoplasm
+190 more · plasma cell myeloma · central nervous system neoplasm · giant cell glioblastoma · hepatocellular carcinoma · non-small cell lung carcinoma · prostate cancer · childhood malignant neoplasm · endometrial serous adenocarcinoma · Hodgkins lymphoma · lymphoma · melanoma · sarcoma · soft tissue sarcoma · anaplastic astrocytoma · anaplastic oligodendroglioma · breast cancer · diffuse large B-cell lymphoma · endometrial cancer · follicular lymphoma · glioblastoma · high grade malignant neoplasm · kidney cancer · lung carcinoid tumor · neoplasm · neuroblastoma · non-Hodgkin lymphoma · ovarian cancer · ovarian carcinoma · prostate adenocarcinoma · urinary bladder cancer · uterine corpus sarcoma · Waldenstrom macroglobulinemia · alveolar rhabdomyosarcoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · brain neoplasm · breast carcinoma · carcinoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · clear cell renal carcinoma · colorectal cancer · colorectal carcinoma · cutaneous melanoma · diffuse astrocytoma · endometrial adenosquamous carcinoma · endometrial clear cell adenocarcinoma · fallopian tube cancer · female reproductive system neoplasm · head and neck cancer · head and neck squamous cell carcinoma · hormone-resistant prostate carcinoma · male breast carcinoma · marginal zone lymphoma · metastatic melanoma · osteosarcoma · ovarian germ cell tumor · pancreatic adenocarcinoma · pancreatic endocrine carcinoma · PPoma · primary peritoneal carcinoma · prostate neoplasm · refractory malignant neoplasm · small cell lung carcinoma · squamous cell carcinoma · urothelial carcinoma · uterine carcinosarcoma · acute leukemia of ambiguous lineage · acute lymphoblastic leukemia · acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute promyelocytic leukemia · adenocarcinoma · adenoma of pancreas · adult acute lymphoblastic leukemia · adult hepatocellular carcinoma · adult oligodendroglioma · alveolar soft part sarcoma · B-cell childhood acute lymphoblastic leukemia · B-cell chronic lymphocytic leukemia · B-cell non-Hodgkin lymphoma · botryoid rhabdomyosarcoma · brain cancer · brainstem neoplasm · breast neoplasm · Burkitt lymphoma · carcinoid tumor · carcinoma of pharynx · Castleman disease · castration-resistant prostate carcinoma · central nervous system disorder · cervical adenosquamous carcinoma · cervical cancer · cervical carcinoma · childhood acute lymphoblastic leukemia · childhood epithelioid sarcoma · childhood pleomorphic rhabdomyosarcoma · chronic myelomonocytic leukemia · colonic neoplasm · cutaneous neuroendocrine carcinoma · diffuse intrinsic pontine glioma · digestive system neuroendocrine tumor, grade 1/2 · endometrioid adenocarcinoma · Erdheim-Chester disease · Ewing sarcoma/peripheral primitive neuroectodermal tumor · fallopian tube carcinoma · female breast carcinoma · gastrointestinal stromal tumor · glioma · glucagonoma · hepatoblastoma · hereditary pheochromocytoma-paraganglioma · hypopharynx squamous cell carcinoma · large-cell immunoblastic lymphoma · larynx verrucous carcinoma · leukemia · leukemia, myeloid, accelerated-phase · lip and oral cavity carcinoma · liver and intrahepatic bile duct neoplasm · liver cancer · lung cancer · lymphangioleiomyomatosis · lymphoblastic lymphoma · major salivary gland carcinoma · male reproductive system neoplasm · malignant epithelial tumor of ovary · malignant pancreatic neoplasm · malignant peripheral nerve sheath tumor · malignant sex cord stromal tumor of ovary · MALT lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · medullary thyroid gland carcinoma · mesothelial neoplasm · metastatic squamous cell carcinoma · mixed glioma · mucosal melanoma · myelodysplastic syndrome · myelodysplastic syndrome with excess blasts · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · NF2-related schwannomatosis · nodal marginal zone B-cell lymphoma · oropharynx squamous cell carcinoma · ovarian carcinosarcoma · ovarian clear cell cystadenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian sarcoma · ovarian seromucinous carcinoma · ovarian serous surface papillary adenocarcinoma · pancreatic gastrinoma · pancreatic insulinoma · pancreatic somatostatinoma · paraganglioma · pediatric angiosarcoma · pediatric fibrosarcoma · pediatric liposarcoma · peripheral T-cell lymphoma, not otherwise specified · peritoneum cancer · pheochromocytoma · pilocytic astrocytoma · pineal body neoplasm · pineal gland astrocytoma · primary central nervous system lymphoma · prostate carcinoma · refractory anemia with excess blasts in transformation · relapsing-remitting multiple sclerosis · renal pelvis/ureter urothelial carcinoma · respiratory tract neoplasm · rhabdomyosarcoma · rhabdomyosarcoma with mixed embryonal and alveolar features · rheumatoid arthritis · salivary gland squamous cell carcinoma · spindle cell rhabdomyosarcoma · splenic marginal zone lymphoma · subependymal giant cell astrocytoma · synovial sarcoma · T-cell childhood acute lymphocytic leukemia · T-cell non-Hodgkin lymphoma · thyroid cancer · thyroid gland carcinoma · tongue carcinoma · triple-negative breast carcinoma · urethra cancer · uterine corpus cancer · verrucous carcinoma of oral cavity · desmoplastic small round cell tumor · Ewing sarcoma · limb ischemia · peripheral arterial disease
Investigated by
National Cancer Institute (NCI) · Wyeth is now a wholly owned subsidiary of Pfizer · Pfizer · M.D. Anderson Cancer Center · National Comprehensive Cancer Network · Washington University School of Medicine
+123 more · AstraZeneca · Genentech, Inc. · Memorial Sloan Kettering Cancer Center · NRG Oncology · Charite University, Berlin, Germany · Dana-Farber Cancer Institute · Puma Biotechnology, Inc. · AEterna Zentaris · AVEO Pharmaceuticals, Inc. · American Society of Clinical Oncology · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Bristol-Myers Squibb · Canadian Cancer Trials Group · Celgene Corporation · Central European Society for Anticancer Drug Research · City of Hope Medical Center · Duke University · Emory University · Hellenic Cooperative Oncology Group · Jonsson Comprehensive Cancer Center · Massachusetts General Hospital · Millennium Pharmaceuticals, Inc. · NATL COMP CA NETWORK · New Mexico Cancer Research Alliance · Novartis · Radboud University Medical Center · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · University of California, San Francisco · University of Tennessee Cancer Institute · University of Wisconsin, Madison · AGO Study Group · Academic Medical Center - University of Amsterdam · Alliance for Clinical Trials in Oncology · Andrew B Lassman, MD · Barrow Neurological Institute · Bayer · Boehringer Ingelheim · Cardiff University · Case Comprehensive Cancer Center · Centre Leon Berard · Children's Hospital of Orange County · Chinese University of Hong Kong · ClinAssess · Columbia University · Covance · Cristiana Sessa · Dartmouth-Hitchcock Medical Center · EMD Serono · Eli Lilly and Company · European Organisation for Research and Treatment of Cancer - EORTC · Federation Francophone de Cancerologie Digestive · Fox Chase Cancer Center · French Innovative Leukemia Organisation · GIMEMA Foundation · Georg Hess, MD · Georgetown University · German Cancer Aid · German Cancer Research Center · GlaxoSmithKline · Goethe University · Gustave Roussy, Cancer Campus, Grand Paris · Gynecologic Oncology Group · Hannover Medical School · Hoffmann-La Roche · Institut Bergonié · Ivy Brain Tumor Center · Janssen Research & Development, LLC · Johann Wolfgang Goethe University Hospital · Johannes Gutenberg University Mainz · Loyola University · Ludwig-Maximilians - University of Munich · Mathias Witzens-Harig · McMaster University · all 129 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (3) US (FDA) TORISEL 2010-04-26 – 2012-05-30 fda.gov
Approved EU (EMA) Torisel 2007-11-19 europa.eu
Approved US (FDA) TORISEL 2007-05-30 fda.gov

Trials 194 · started per year

today
US approved 2007
EU approved 2007
1
4
4
6
10
9
6
14
19
38
33
13
15
3
3
6
3
1
2
1
1
1
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT05773326 May 2023 → Feb 2025 glioblastoma Nader Sanai Terminated No outcome recorded
Phase 0 NCT02446431 Jul 2014 → Jul 2024 overdue cancer Miller Children's & Women's Hospital Long Beach Recruiting No outcome recorded
Phase 0 NCT01417065 Aug 2010 → Jun 2014 cancer of unknown primary site M.D. Anderson Cancer Center Completed No outcome recorded
Phase 169 trials
Phase 1 NCT03203525 Jun 2020 → Dec 2026 expected colorectal carcinoma, metastatic malignant neoplasm M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT02420613 Oct 2015 → Mar 2025 diffuse intrinsic pontine glioma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT02389309 Oct 2015 → Oct 2027 expected brain neoplasm, high grade malignant neoplasm M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT01614197 Jul 2015 → Dec 2019 childhood acute lymphoblastic leukemia, lymphoblastic lymphoma, peripheral T-cell lymphoma, not otherwise specified Therapeutic Advances in Childhood Leukemia Consortium Completed No outcome recorded
Phase 1 NCT02343718 Jun 2015 → Sep 2017 cancer, central nervous system disorder, lymphoma Canadian Cancer Trials Group Completed No outcome recorded
Phase 1 NCT02238496 Dec 2014 → Oct 2017 anaplastic astrocytoma, anaplastic oligodendroglioma, brain cancer, glioblastoma +1 Andrew B Lassman, MD Completed No outcome recorded
Phase 1 NCT01902160 Sep 2013 → May 2015 Hodgkins lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01596140 Dec 2012 → Jun 2020 cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT01552434 Oct 2012 → May 2026 Castleman disease, Erdheim-Chester disease, NF2-related schwannomatosis, breast carcinoma +11 M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 1 NCT01712828 Oct 2012 → Jan 2013 Celgene Corporation Completed No outcome recorded
Phase 1/231 trials
Phase 1/2 NCT03158389 May 2018 → Feb 2023 adult glioblastoma University Hospital Heidelberg Completed No outcome recorded
Phase 1/2 NCT02423954 Apr 2015 → Nov 2017 cancer of unknown primary site, colorectal carcinoma, endometrial cancer, malignant pancreatic neoplasm +2 Western Regional Medical Center Terminated No outcome recorded
Phase 1/2 NCT01614301 May 2012 → May 2014 melanoma University of Regensburg Unknown No outcome recorded
Phase 1/2 NCT01389427 Nov 2011 → May 2015 mantle cell lymphoma The Lymphoma Academic Research Organisation Completed No outcome recorded
Phase 1/2 NCT01381692 Jul 2011 → Dec 2014 Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT01335074 Apr 2011 → Dec 2013 hepatocellular carcinoma Philipps University Marburg Withdrawn No outcome recorded
Phase 1/2 NCT01206036 Jul 2010 → Sep 2014 prostate neoplasm Central European Society for Anticancer Drug Research Completed No outcome recorded
Phase 1/2 NCT01170052 May 2010 → Apr 2012 mantle cell lymphoma Charite University, Berlin, Germany Withdrawn No outcome recorded
Phase 1/2 NCT01076543 Apr 2010 → Dec 2017 Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT01111825 Apr 2010 → Jul 2016 breast cancer Puma Biotechnology, Inc. Completed No outcome recorded
Phase 277 trials
Phase 2 NCT03297606 Mar 2018 → Dec 2026 expected non-Hodgkin lymphoma, plasma cell myeloma Canadian Cancer Trials Group Recruiting No outcome recorded
Phase 2 NCT02788201 Mar 2017 → Oct 2019 urinary bladder cancer, urothelial carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT02693535 Mar 2016 → Dec 2027 expected non-Hodgkin lymphoma, plasma cell myeloma American Society of Clinical Oncology Recruiting No outcome recorded
Phase 2 NCT02560012 Jan 2016 → Jul 2017 renal cell carcinoma The University of Texas Health Science Center, Houston Terminated No outcome recorded
Phase 2 NCT02142036 May 2014 → Aug 2018 metastatic malignant neoplasm Oslo University Hospital Completed No outcome recorded
Phase 2 NCT01827267 Jul 2013 → Sep 2016 carcinoma Puma Biotechnology, Inc. Completed No outcome recorded
Phase 2 NCT01767194 Feb 2013 → Jun 2018 ganglioneuroblastoma, neuroblastoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT01392183 Oct 2012 → Sep 2019 kidney cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2 NCT01687673 Oct 2012 → Apr 2016 hepatocellular carcinoma University of California, San Francisco Completed No outcome recorded
Phase 2 NCT01653067 Sep 2012 → Jun 2018 diffuse large B-cell lymphoma Mathias Witzens-Harig Unknown No outcome recorded
Phase 38 trials
Phase 3 NCT02567435 Jun 2016 → Jun 2023 overdue alveolar rhabdomyosarcoma, botryoid rhabdomyosarcoma, spindle cell rhabdomyosarcoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 3 NCT01646021 Dec 2012 → Jun 2015 mantle cell lymphoma Janssen Research & Development, LLC Completed No outcome recorded
Phase 3 NCT00980460 Sep 2009 → Jun 2020 hepatoblastoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 3 NCT00631371 Apr 2008 → Apr 2012 renal cell carcinoma Pfizer Completed No outcome recorded
Phase 3 NCT00474786 Sep 2007 → Jan 2012 renal cell carcinoma Pfizer Completed No outcome recorded
Phase 3 NCT00117598 May 2005 → Aug 2007 lymphoma Pfizer Completed No outcome recorded
Phase 3 NCT00083993 May 2004 → Oct 2006 breast cancer, metastatic malignant neoplasm Wyeth is now a wholly owned subsidiary of Pfizer Terminated No outcome recorded
Phase 3 NCT00065468 Jul 2003 → Jun 2006 renal cell carcinoma Pfizer Completed No outcome recorded
Phase not applicable6 trials
NCT04199026 Feb 2025 → Dec 2028 expected sarcoma M.D. Anderson Cancer Center Recruiting No outcome recorded
NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
NCT01326468 Dec 2011 → Dec 2016 head and neck cancer Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Withdrawn No outcome recorded
NCT01369433 Jun 2010 → Jun 2015 cancer AVEO Pharmaceuticals, Inc. Terminated No outcome recorded
NCT01404104 Sep 2008 → Aug 2014 renal cell carcinoma St. Joseph's Healthcare Hamilton Completed No outcome recorded
NCT00235794 Jan 2004 → Sep 2007 prostate neoplasm Wyeth is now a wholly owned subsidiary of Pfizer Completed No outcome recorded
Also used as a comparator or background therapy in 11 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT00909831 Background Oct 2008 → May 2012 cancer of unknown primary site Abramson Cancer Center at Penn Medicine Completed No outcome recorded
Phase 1 NCT00659568 Background Mar 2008 → Feb 2010 breast cancer, cancer of unknown primary site, endometrial cancer, kidney cancer +2 London Health Sciences Centre Completed No outcome recorded
Phase 1 NCT00593060 Background Nov 2007 → Oct 2009 colorectal adenocarcinoma Jeffrey W. Clark, MD Completed No outcome recorded
Phase 25 trials
Phase 2 NCT03942601 Comparator Oct 2019 → Apr 2021 peripheral arterial disease Mercator MedSystems, Inc. Terminated No outcome recorded
Phase 2 NCT02908035 Comparator Mar 2017 → Sep 2020 limb ischemia Mercator MedSystems, Inc. Unknown No outcome recorded
Phase 2 NCT02187302 Comparator Jul 2014 → Jul 2016 renal cell carcinoma NewLink Genetics Corporation Completed No outcome recorded
Phase 2 NCT01946529 Comparator Dec 2013 → Aug 2015 overdue Ewing sarcoma, desmoplastic small round cell tumor St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 2 NCT01396408 Comparator Feb 2012 → Jul 2015 overdue Canadian Cancer Trials Group Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT04433572 Comparator Jul 2025 → Feb 2028 expected limb ischemia, peripheral arterial disease Mercator MedSystems, Inc. Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT01180049 Comparator Mar 2011 → Nov 2015 non-Hodgkin lymphoma Pfizer Completed No outcome recorded
Phase not applicable1 trial
NCT03571438 Comparator Oct 2017 → Sep 2022 kidney cancer University Hospital, Grenoble Unknown No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 208 sources stand behind the page.

FieldValueCited text
Known as Temsirolimus “Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression” NCT01251458
200

“Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 Nov 2017

Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.” PMID 17538086 May 2007

“Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients” NCT00919035

Temsirolimus (Torisel™) administered in intravenous (IV) at day 2, day 8 and day 15” NCT01389427

“Tamoxifen, Temsirolimus, Teniposide” NCT02788201

“Sunitinib Temsirolimus Thioguanine” NCT02551718

TemsirolimusNCT01404104

TemsirolimusNCT02142036

NCT01008917

NCT00631371

NCT00417677

NCT04433572

NCT00235794

NCT01079286

NCT01180049

NCT01111825

NCT01090466

NCT01851408

NCT00784914

NCT01381692

NCT00281957

NCT00408655

NCT03158389

NCT01281917

NCT02238496

NCT00398515

NCT00770731

NCT00062751

NCT02693535

NCT01529593

NCT00512668

NCT01083368

NCT00699491

NCT01049841

NCT00022464

NCT01061606

NCT01016015

NCT01529138

NCT00887640

NCT00101088

NCT00376688

NCT00877773

NCT01404104

NCT01025453

NCT01020305

NCT00996346

NCT02446431

NCT00782275

NCT02567435

NCT00808899

NCT00075647

NCT00775593

NCT01653067

NCT01076543

NCT00838955

NCT01122615

NCT00079456

NCT01256385

NCT00563147

NCT01281943

NCT01065662

NCT00329719

NCT00761644

NCT00086840

NCT00316849

NCT01614197

NCT01010126

NCT02215720

NCT00072176

NCT00275093

NCT02093598

NCT01625156

NCT01015664

NCT02560012

NCT01614301

NCT05773326

NCT00678769

NCT01182883

NCT01375829

NCT01614795

NCT00909831

NCT01051557

NCT01196429

NCT00022724

NCT00838539

NCT01646021

NCT01170052

NCT01902160

NCT00949325

NCT01166126

NCT01611116

NCT01222715

NCT01567930

NCT01378377

NCT00523432

NCT00016328

NCT00796796

NCT01078142

NCT01183663

NCT01111448

NCT01246817

NCT00028028

NCT03297606

NCT00474786

NCT00397982

NCT00071968

NCT00429793

NCT00980460

NCT00349206

NCT00255658

NCT01403415

NCT00610493

NCT01079767

NCT01369433

NCT00087074

NCT00949026

NCT00982631

NCT00788580

NCT00703625

NCT01072890

NCT01026792

NCT01026623

NCT01141244

NCT01535989

NCT02389309

NCT01198184

NCT01206140

NCT00378703

NCT01172769

NCT01206036

NCT02423954

NCT00659568

NCT00494091

NCT00112736

NCT01827267

NCT00926107

NCT00729586

NCT00098501

NCT04199026

NCT03203525

NCT00977574

NCT01392183

NCT01174199

NCT01326468

NCT00942747

NCT01050985

NCT00083993

NCT00921310

NCT01596140

NCT00880282

NCT00979966

NCT01460979

NCT00619268

NCT00800917

NCT00093782

NCT00112476

NCT00033267

NCT01335074

NCT00045370

NCT00600496

NCT02908035

NCT00003712

NCT01767194

NCT01712828

NCT01187199

NCT01552434

NCT02343718

NCT00079235

NCT01264341

NCT00290472

NCT01087554

NCT01946529

NCT00703170

NCT00723255

NCT00593008

NCT01687673

NCT00335764

NCT02420613

NCT01019434

NCT00593060

NCT00998036

NCT01155258

NCT01827943

NCT01417065

NCT00787969

NCT01204450

NCT00693433

NCT03571438

NCT00770263

NCT01396408

NCT01016769

NCT00012142

NCT00084916

NCT01548482

NCT00109967

NCT01009203

NCT01517243

NCT00117598

NCT03942601

NCT00827684

Known as CCI-779 “A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or...” NCT01182883
17

“The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly” NCT00065468

“Randomized, Double-Blind, Placebo-Controlled, Phase II Study Of Intravenous CCI-779 Administered Weekly To Patients With Androgen-Independent Prostate Cancer” NCT00012142

“Temsirolimus (CCI-779) has been widely investigated in different clinical settings and is presently registered for treatment of renal cell carcinomas.” NCT00827684

“Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse” NCT00926107

“Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily” NCT00062751

CCI-779 (Temsirolimus; NSC-683864; IND-XXXX)” NCT00788580

“Temsirolimus = Toricel or CCI-779NCT00996346

“temsirolimus (CCI-779)” NCT00083993

“Temsirolimus (CCI-779)” NCT00494091

“Temsirolimus (CCI-779)” NCT00117598

CCI-779 (temsirolimus)” NCT00523432

CCI-779NCT00703625

CCI-779NCT01076543

NCT00483262

NCT00228397

NCT00076206

NCT00112840

Known as CCI-779 Rapamycin Analog CCI-779 Rapamycin AnalogNCT01076543
Known as NSC 683864 “Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas” NCT01016015
1

“CCI-779 (Temsirolimus; NSC-683864; IND-XXXX)” NCT00788580

Known as TEM “The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential.” PMID 34320785 Jul 2022
1

“Determine the maximum tolerated dose of hydroxychloroquine (HCQ) in combination with temsirolimus (TEM) in patients with metastatic refractory solid tumors.” NCT00909831

Known as Toricel “Temsirolimus = Toricel or CCI-779” NCT00996346
Known as Torisel “Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression” NCT01251458
8

“A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer” NCT00982631

“Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly.” NCT00474786

“Temsirolimus (Torisel™) administered in intravenous (IV) at day 2, day 8 and day 15” NCT01389427

“This study uses one trialdrug: Temsirolimus (sometimes called Torisel ® ).” NCT01246817

“adventitial delivery of temsirolimus (Torisel)” NCT02908035

Torisel (Temsirolimus)” NCT00770731

NCT00919035

NCT00106353

Known as Torisel (temsirolimus) Torisel (temsirolimus)NCT00563147
Action Inhibit “a specific inhibitor of the mammalian target of rapamycin kinase” PMID 17538086 May 2007
1

“FK506-binding protein 1A inhibitor” CHEMBL1201182

Modality Small molecule “Temsirolimus (CCI-779) is a soluble ester analogue of rapamycin (sirolimus)” NCT00703625
Route Intravenous “CCI-779 IV over 30 minutes” NCT00003712
Target FKBP1A “FK506-binding protein 1A inhibitor” CHEMBL1201182
Target MTOR “mammalian target of rapamycin kinase” PMID 17538086 May 2007